share_log

Resverlogix Announces Warrant Repricing and One-Year Extension

Resverlogix Announces Warrant Repricing and One-Year Extension

Resverlogix 宣佈認股權證重新定價並延長一年
newsfile ·  2023/06/30 06:00

Calgary, Alberta--(Newsfile Corp. - June 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces that certain of its 27,461,157 common share purchase warrants (the "Warrants") will be amended. Commencing on July 17, 2023, the exercise price of 24,508,489 Warrants (currently exercisable at prices ranging from $0.24 to $1.00 per share) will be reduced to $0.20 per share, and the expiry date of 10,713,505 of the Warrants that currently expire between April 26, 2024 and June 6, 2025 will be extended by one year. All other terms of all the Warrants will remain unchanged. 1,500,000 warrants held by insiders of the Company will not be amended; the warrants listed for trading that expired on June 7, 2023 were not eligible for amendment.

加拿大阿爾伯塔省卡爾加裡-(Newsfile Corp.-2023年6月29日)-Resverlogix Corp.(多倫多證券交易所股票代碼:RVX)(以下簡稱“Resverlogix”或“公司”)宣佈,其27,461,157份普通股認購權證(以下簡稱“認股權證”)的某些部分將被修訂。自2023年7月17日起,24,508,489份認股權證的行使價格(目前可行使的價格為0.24美元至每股1.00美元)將降至每股0.20美元,目前到期的10,713,505份權證的到期日為2024年4月26日和2025年6月6日將延長一年。所有認股權證的所有其他條款將保持不變。本公司內部人士持有的1,500,000份權證將不會修訂;於2023年6月7日到期的上市交易權證不符合修訂資格。

The Company has received approval of the extension and repricing from the TSX, subject to satisfaction of customary conditions. The net proceeds from the exercise of Warrants will be used for research and development activities, general and administrative expenses, working capital needs and general corporate purposes.

該公司已獲得多倫多證券交易所對延期和重新定價的批准,但須滿足慣常條件。行使認股權證所得款項淨額將用於研發活動、一般及行政開支、營運資金需要及一般企業用途。

About Resverlogix

關於Resverlogix

Founded in 2001, Resverlogix is a Calgary-based, late-stage, biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix成立於2001年,是一家總部設在卡爾加裡的晚期生物技術公司,是表觀遺傳學領域的世界領先者,目標是為慢性病患者開發一流的治療方法。

Our new class of epigenetic therapies are designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.

我們的新型表觀遺傳療法旨在調節致病基因的表達。我們的目標是通過將因心血管疾病等嚴重疾病而改變的生物功能恢復到更健康的狀態來改善患者的生活。

The Company's clinical program is focused on evaluating our lead candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post COVID-19 conditions.

該公司的臨床計劃側重於評估我們治療心血管疾病和相關合並症以及新冠肺炎後遺症的主要候選藥物阿帕貝酮。

Resverlogix has partnered with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).

Resverlogix與全球生命科學行業下一代商業服務的先驅EVERSANA公司建立了合作夥伴關係,以支持用於心血管疾病、新冠肺炎後疾病和肺動脈高壓的阿帕貝酮在加拿大和美國的快速商業化。Resverlogix普通股在多倫多證券交易所(多倫多證券交易所市場代碼:RVX)交易。

Follow us on:

請跟隨我們:

  • Twitter: @Resverlogix_RVX
  • LinkedIn:
  • 推特:@Resverlogix_rvx
  • LinkedIn:

For further information please contact:

欲瞭解更多資訊,請聯繫:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252

投資者關係
電子郵件:ir@resverlogix.com
電話:403-254-9252

Forward-Looking Statements:

前瞻性陳述:

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the repricing and extension of the Company's warrants. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

本新聞稿可能包含某些根據適用的加拿大證券法定義的不基於歷史事實的前瞻性資訊,包括但不限於包含“相信”、“預期”、“計劃”、“打算”、“將”、“應該”、“預期”、“繼續”、“估計”、“預測”以及其他類似表述的陳述。特別是,本新聞稿包括與公司認股權證的重新定價和延長有關的前瞻性資訊。我們的實際結果、事件或發展可能與這些前瞻性陳述中明示或暗示的結果、事件或發展大不相同。我們不能保證任何事件或預期都會發生或實現。就其性質而言,前瞻性陳述受許多假設和風險因素的影響,包括在我們的年度資訊表格和最新的MD&A中討論的那些,這些陳述通過引用併入本文,並可通過SEDAR獲得,網址為:。本新聞稿中包含的前瞻性陳述明確地受到這一警示聲明的限制,並且是在本新聞稿發佈之日作出的。除法律要求外,公司沒有任何意圖,也沒有義務或責任更新或修改任何前瞻性陳述,無論是由於新資訊、未來事件或其他原因。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論